NET PROFIT (x1000 NOK)
EMPLOYEES
Chosa Oncology AB
Closing information (x1000 NOK)
| Closing information | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
283
|
551
|
1,396 |
| Earnings before taxes |
-9,894
|
-24,062
|
-38,888 |
| EBITDA |
-9,313
|
-23,038
|
-38,892 |
| Total assets |
17,108
|
19,679
|
26,377 |
| Current assets |
7,253
|
9,649
|
26,377 |
| Current liabilities |
2,859
|
2,041
|
17,822 |
| Equity capital |
14,249
|
17,638
|
8,555 |
| - share capital |
13,170
|
11,829
|
3,243 |
| Employees (average) |
1
|
1
|
4 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
83.3%
|
89.6%
|
32.4% |
| Turnover per employee |
0
|
0
|
0 |
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-56.2%
|
-119.5%
|
-142.1% |
| Current ratio |
253.7%
|
472.8%
|
148.0% |
| Return on equity (ROE) |
-69.4%
|
-136.4%
|
-454.6% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
0
|
-3
|
0 |
| Chg. No. of employees % |
0%
|
-75%
|
0% |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.